Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China.

Figures

• 

  Figure 1. Variable assessment windows relative to the study index date for medication-specific cohorts. CKD=chronic kidney disease; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HCU=healthcare utilization; SGLT2i=sodium-glucose cotransporter 2 inhibitor; T1D=type 1 diabetes mellitus; T2D=type 2 diabetes mellitus. aStudy period: 01 January 2012 through 31 December 2019. bSGLT2i, GLP 1 RA, sMRA, ACEi, ARB. cConditions requiring ≥365 days for accurate assessment, including hypertension, glomerulonephritis, renovascular disease, polycystic kidney disease, autoimmune disease and amputations. dOutcome-specific exclusion criteria were assessed in outcome-specific washout periods; outcome-specific washout periods were applied separately before outcome-specific analyses. eCensored at the earliest of the end of the study period (31 December 2019), disenrollment, death, T1D diagnosis, discontinuation of medication class or development of kidney failure.